Home

Rick Haas

Rick L.M. Haas is a soft tissue sarcoma focused radiation-oncologist from the NKI-AVL in Amsterdam, the Netherlands, where he works for almost 25 years as a staff member of the Department of Radiotherapy.
He is an active member of CTOS (Board of Directors 2015-2017), the EORTC-STBSG (President of the Local Treatment Subcommittee), and the Sarcoma Patients Euronet (SPAEN) Patient Advocacy Organization (Medical Advisory Board). He is also a member of the Board of EMSOS and a Faculty Member of the ESMO initiated World Sarcoma Network.
His current research interests focus mainly on sarcomas where he has initiated several clinical phase I (NCT01985295), II (NCT02575066, NCT02106312) and III trials (NCT01344018). Dr. Rick Haashas authored or co-authored over 100 scientific papers as well as contributed to several books on sarcomas and lymphomas.

Piotr Rutkowski

Piotr Rutkowski is Professor of Surgical Oncology and currently heads the Department of Soft Tissue/Bone Sarcoma and Melanoma at Maria Sklodowska-Curie Institute – Oncology Center in Warsaw, where he acts also as Plenipotentiary of Head Director for Clinical Trials and VicePresident of Scientific Council.

He obtained his medical degree from the Medical University of Lodz, Poland and received his PhD, in 2001, from the Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology for his work on cytokine levels in patients with soft tissue and bone sarcomas.

Prof Rutkowski is vice President of the Sarcoma Subdomain of EUROCAN (European network for Rare adult solid Cancer) and an active member of the EORTC Soft Tissue and Bone Sarcoma Group, where he chaired the Local Treatment Subcommittee and the Membership Committee of the EORTC Board.  He is a former member of Board of Directors of the Connective Tissue Oncology Society (CTOS).

Dr. Rutkowski has authored or co-authored over 140 scientific papers in Polish and international journals, and is co-author of national and international recommendations for sarcoma and melanoma.

Relevant publications

63. Rutkowski, W. Ruka. Emergency surgery in the era of molecular treatment of solid tumors. Lancet Oncol 2009; Feb;10(2):157-63.

Rutkowski P, Wozniak A, Dębiec-Rychter M, Kąkol M, Dziewirski W, Zdzienicki M, Ptaszynski K, Jurkowska M, Limon J,Siedlecki JA. Clinical utility of the new American Joint Committee on Cancer staging system for gastrointestinal stromal tumors: Current overall survival after primary tumor resection. Cancer 2011 Nov 1;117(21):4916-24.

Florence Duffaud

Florence Duffaud (MD, PhD) underwent medical training and completed her medical oncology fellowship and residency at the University of Medicine of Marseilles, France. She completed a one-year fellowship at the EORTC data centre in Brussels.
She is currently a Professor of Oncology at the University of Medicine of Marseilles, at Aix-Marseilles University (AMU), and the head of the medical Oncology Unit at La Timone University Hospital, in Marseilles. Her research interests are focused on novel therapies, and novel therapeutic strategies on soft tissues sarcoma, bone sarcoma and GISTs. She has led and/or developed multiple investigational clinical trials for soft tissues and bone sarcomas and GISTs as, principal investigator or site principal investigator.
She serves on the French Sarcoma Group (FSG) board and is a member of the FSG and of the soft tissue and bone sarcoma group (STBSG) of the EORTC. She is reviewer for several oncological journals.

Relevant publications

Duffaud F, Piperno-Neumann S, Penel N, Blay JU. From rare to well-done : importance of rare tumors in cancer therapeutic advances. Oncotarget 2019 june 18 ; 10(40)/ 3998-99

Duffaud F, Mir O, Boudou-Rouquette P, Piperno-Neumann S, Penel N, Bompas E, Delcambre C, Kalbacher E, Italiano A, Collard O, Vhvreau C, Saada E, Isambert N, Delaye J, Schiffer C, Bouvier C, Vidal V, Chabaud S, Blay JY. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoa : a non-comparative radnomised, double-blind, placebo-controled, phase2 study. Lancet Oncol 2019 ; 20 (1) : 120-33.

Gerlderblom H, Cropet C Chevreau C, Boyle R, Tattersall M, Stacchiotti S, Italiano A, Piperno-Neumann S, Le Cesne A, Ferraresi V, Penel N, Duffaud F, Cassier P, Toulmonde M, Casali P, Taieb S, Guillemaut S, Metzger S, Perol D, BLay JY. Nilotinib in locally advanced pigmented villo-nodular synovitis, single-arm, open-label phase 2 trial. Lancet Oncol 2018 ; 19(5) : 639-48

Duffaud F, Meeus P, Bertucci F, Delhorme JB, Stoeckle E5, Isambert N, Bompas E, Gagniere J, Bouché O, Toulmonde M, Salas S, Blay JY, Bonvalot S; French Sarcoma Group. Patterns of care and clinical outcomes in primary oesophageal gastrointestinal stromal tumours (GIST): A retrospective study of the French Sarcoma Group (FSG). Eur J Surg Oncol. 2017 Jun;43(6):1110-1116.

Pautier P, Floquet A, Chevreau C, Penel N, Guillemet C, Delcambre C, Cupissol D, Selle F, Isambert N, Piperno-Neumann S, Thyss A, Bertucci F, Bompas E, Alexandre J, Collard O, Lavau-Denes S, Soulié P, Toulmonde M, Le Cesne A, Lacas B, Duffaud F ; French Sarcoma Group. Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial. Lancet Oncol. 2015 ; 16(4) : 457-64

Duffaud F, Sleijfer S, Litière S, Ray-Coquard I, Le Cesne A, Papai Z, Judson I, Schöffski P, Chawla SP, Dewji R, Marreaud S, Verweij J, van der Graaf WT. Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials. Eur J Cancer. 2015 Nov;51(17):2615-23.

Pautier P, Floquet A, Gladieff L, Bompas E, Ray-Coquard I, Piperno-Neumann S, Selle F, Guillemet C, Weber B, Largillier R, Bertucci F, Opinel P, Duffaud F, Reynaud-Bougnoux A, Delcambre C, Isambert N, Kerbrat P, Netter-Pinon G, Pinto N, Duvillard P, Haie-Meder C, Lhommé C, Rey A. A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma Group. Ann Oncol. 2013; 24(4): 1099-104.

Pautier, A Floquet, N Penel, S Piperno-Neumann, N Isambert, A Rey, E Bompas, A Cioffi, C Delcambre, D Cupissol, F Collin, JY Blay, M Jimenez, F Duffaud. Multicenter randomized and stratified phase II study of Gemcitabine versus Gemcitabine and Docetaxel in patients with metastatic or relapsed uterine or soft tissue leiomyosarcomas: a FNCLCC French Sarcoma Group study (TAXOGEM study). The Oncologist 2012;17(9):1213-20.

Duffaud F, Egerer G, Ferrari S, Rasssam H, Boecker U, Bui-Nguyen B. A phase II of second-line pemetrexed in adults with advanced/metastatic osteosarcoma. Eur J Cancer 2012, mar 48(4): 564-79.

Sylvie Bonvalot

Dr Sylvie Bonvalot is an oncological surgeon specializing in soft-tissue sarcomas at Institut Curie, in Paris, where she currently heads the Visceral and sarcoma Surgery Department. She is an Associate Professor at the Collège de Medécine des hôpitaux de Paris.
Sylvia Bonvalot has specialized in surgery of sarcoma and complex tumors for around twenty years; before joining Institut Curie, she worked at Gustave Roussy from 1994 to 2015.
She coordinates several international studies on sarcoma or complex tumors of the abdomen and soft tissues of the limbs, and sits on the scientific boards of several French and European medical patient organizations or associations.
She is an active member of the French sarcoma group and of several European societies (including ESSO, ESMO and EORTC). She has standardized and published surgical sarcoma techniques in international journals, and is the author of over 170 articles on the subject.